|
US2856420A
(en)
|
1955-12-15 |
1958-10-14 |
Minnesota Mining & Mfg |
Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
|
|
US3340299A
(en)
|
1964-03-27 |
1967-09-05 |
Air Reduction |
Tetrasubstituted ethylene diamines
|
|
GB1277947A
(en)
|
1968-08-22 |
1972-06-14 |
Armour Ind Chem Co |
Compositions and method for controlling insect pests
|
|
US4491583A
(en)
|
1970-08-07 |
1985-01-01 |
Pfizer Inc. |
Interferon induction in animals by amines
|
|
US3729564A
(en)
|
1970-12-16 |
1973-04-24 |
Pfizer |
N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents
|
|
JPS5122416B2
(enExample)
|
1972-11-11 |
1976-07-09 |
|
|
|
JPS5718088B2
(enExample)
|
1972-06-22 |
1982-04-14 |
|
|
|
DE2633615C3
(de)
|
1976-07-27 |
1981-08-13 |
Bayer Ag, 5090 Leverkusen |
Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien
|
|
DE3050800C2
(enExample)
|
1979-03-22 |
1989-06-22 |
Continental Pharma Inc., Bruessel/Bruxelles, Be |
|
|
US4883751A
(en)
|
1986-05-28 |
1989-11-28 |
New York University |
Specific immunoassay for heparin
|
|
US5858980A
(en)
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
|
JP2588339B2
(ja)
|
1992-06-02 |
1997-03-05 |
花王株式会社 |
新規ジアミノジエステル及びその製造法
|
|
US6197553B1
(en)
|
1994-07-15 |
2001-03-06 |
Merck & Co., Inc. |
Method for large scale plasmid purification
|
|
FR2727679B1
(fr)
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
EP0832271B8
(en)
|
1995-06-07 |
2005-03-02 |
INEX Pharmaceuticals Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5705385A
(en)
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
NZ313839A
(en)
|
1995-07-21 |
1998-12-23 |
Genta Inc |
Amide-based cationic lipids
|
|
DE19605175A1
(de)
|
1996-02-13 |
1997-08-14 |
Sourovoi Andrej Dr |
Lipidverbindungen und deren Verwendung
|
|
JPH103643A
(ja)
|
1996-06-12 |
1998-01-06 |
Fuji Photo Film Co Ltd |
ディスク状磁気記録媒体
|
|
EP0948587B1
(en)
|
1996-10-11 |
2003-05-07 |
Infineum Holdings BV |
Fuel compositions
|
|
CA2217550A1
(en)
|
1996-10-22 |
1998-04-22 |
F. Hoffmann-La Roche Ag |
Cationic lipids for gene therapy
|
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
|
US5965542A
(en)
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
|
US5756785A
(en)
|
1997-03-21 |
1998-05-26 |
Lambent Technologies, Inc. |
Guerbet betaines
|
|
FR2763943B1
(fr)
|
1997-05-28 |
1999-07-09 |
Rhone Poulenc Rorer Sa |
Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
|
|
US6395713B1
(en)
|
1997-07-23 |
2002-05-28 |
Ribozyme Pharmaceuticals, Inc. |
Compositions for the delivery of negatively charged molecules
|
|
EP1041976B1
(en)
|
1997-12-23 |
2006-04-05 |
Inex Pharmaceuticals Corp. |
Polyamide oligomers
|
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
US6986902B1
(en)
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
|
US6013813A
(en)
|
1998-06-17 |
2000-01-11 |
Hansotech Inc |
Guerbet based sorbitan esters
|
|
US6333433B1
(en)
|
1998-11-09 |
2001-12-25 |
Council Of Scientific Industrial Research |
Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
|
|
US6656498B1
(en)
|
1998-11-25 |
2003-12-02 |
Vanderbilt University |
Cationic liposomes for gene transfer
|
|
US5919743A
(en)
|
1998-12-28 |
1999-07-06 |
Petroferm Inc. |
Guerbet branched quaternary compounds in personal care applications
|
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
|
US6211140B1
(en)
|
1999-07-26 |
2001-04-03 |
The Procter & Gamble Company |
Cationic charge boosting systems
|
|
DE69923840T2
(de)
|
1999-09-09 |
2006-04-06 |
Curevac Gmbh |
Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
|
|
GB9930533D0
(en)
|
1999-12-23 |
2000-02-16 |
Mitsubishi Tokyo Pharm Inc |
Nucleic acid delivery
|
|
JP2001338416A
(ja)
|
2000-05-25 |
2001-12-07 |
Sony Corp |
ディスク状磁気記録媒体
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
WO2003059280A2
(en)
|
2002-01-09 |
2003-07-24 |
Elan Pharmaceuticals, Inc. |
Efficient liposomal encapsulation
|
|
JP4111856B2
(ja)
|
2002-04-12 |
2008-07-02 |
昭和電工株式会社 |
安定化されたアスコルビン酸誘導体
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
US6620794B1
(en)
|
2002-07-08 |
2003-09-16 |
Colonial Chemical Inc. |
Guerbet functionalized phospholipids
|
|
WO2004018506A2
(en)
|
2002-08-22 |
2004-03-04 |
Cytos Biotechnology Ag |
Inducible alphaviral/orip based gene expression system
|
|
EP1648519B1
(en)
|
2003-07-16 |
2014-10-08 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
CA2551022C
(en)
|
2003-09-15 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
CA2566559C
(en)
|
2004-05-17 |
2014-05-06 |
Inex Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
EP1766035B1
(en)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
JP5777846B2
(ja)
|
2005-06-15 |
2015-09-09 |
マサチューセッツ インスティテュート オブ テクノロジー |
アミン含有脂質およびその使用
|
|
EP1937213B1
(en)
|
2005-07-27 |
2017-10-25 |
Protiva Biotherapeutics Inc. |
Systems and methods for manufacturing liposomes
|
|
TR201909609T4
(tr)
|
2005-08-23 |
2019-07-22 |
Univ Pennsylvania |
Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
|
|
JP4681425B2
(ja)
|
2005-11-15 |
2011-05-11 |
花王株式会社 |
毛髪弾性改善剤
|
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
ES2430206T3
(es)
|
2006-10-03 |
2013-11-19 |
Tekmira Pharmaceuticals Corporation |
Formulación que contiene lípidos
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008109806A2
(en)
|
2007-03-08 |
2008-09-12 |
Massachusetts Institute Of Technology |
Electrostatic coating of particles for drug delivery
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
EP3156077B1
(en)
|
2007-12-04 |
2022-03-09 |
Arbutus Biopharma Corporation |
Targeting lipids
|
|
WO2009088891A1
(en)
|
2008-01-02 |
2009-07-16 |
Alnylam Pharmaceuticals, Inc. |
Screening method for selected amino lipid-containing compositions
|
|
CA2711240C
(en)
|
2008-01-02 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Liver screening method
|
|
CN101932707B
(zh)
|
2008-01-31 |
2013-08-21 |
库瑞瓦格有限责任公司 |
作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
|
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
|
ES2638448T3
(es)
|
2008-04-15 |
2017-10-20 |
Protiva Biotherapeutics Inc. |
Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
US20120009222A1
(en)
*
|
2008-10-27 |
2012-01-12 |
Massachusetts Institute Of Technology |
Modulation of the immune response
|
|
WO2010054384A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Lipids and compositions for the delivery of therapeutics
|
|
PL4241767T3
(pl)
|
2008-11-10 |
2025-03-03 |
Arbutus Biopharma Corporation |
Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
|
|
CN102231950A
(zh)
|
2008-11-17 |
2011-11-02 |
安龙制药公司 |
用于核酸递送系统的可释放聚合脂质
|
|
EP2391343B1
(en)
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
AU2010245933B2
(en)
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
|
PL3431076T3
(pl)
|
2009-06-10 |
2022-01-31 |
Arbutus Biopharma Corporation |
Ulepszona formulacja lipidowa
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US20120164176A1
(en)
|
2009-07-15 |
2012-06-28 |
Kurt Swanson |
Rsv f protein compositions amd methods for making same
|
|
US20120264810A1
(en)
|
2009-09-22 |
2012-10-18 |
The University Of British Columbia |
Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
US20130022649A1
(en)
|
2009-12-01 |
2013-01-24 |
Protiva Biotherapeutics, Inc. |
Snalp formulations containing antioxidants
|
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
Martin A. Maier |
Lipid particles for delivery of nucleic acids
|
|
JP5902617B2
(ja)
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
EP2567951B1
(en)
|
2010-04-28 |
2018-09-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
WO2011143230A1
(en)
|
2010-05-10 |
2011-11-17 |
Alnylam Pharmaceuticals |
Methods and compositions for delivery of active agents
|
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8865675B2
(en)
|
2010-05-12 |
2014-10-21 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
WO2011149733A2
(en)
|
2010-05-24 |
2011-12-01 |
Merck Sharp & Dohme Corp. |
Novel amino alcohol cationic lipids for oligonucleotide delivery
|
|
NZ605079A
(en)
|
2010-06-03 |
2015-08-28 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
LT2590676T
(lt)
|
2010-07-06 |
2016-10-25 |
Glaxosmithkline Biologicals Sa |
Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
|
|
DK2591114T3
(en)
|
2010-07-06 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
Immunization of large mammals with low doses of RNA
|
|
SI3243526T1
(sl)
|
2010-07-06 |
2020-02-28 |
Glaxosmithkline Biologicals S.A. |
Dostava RNA za sprožitev večih imunskih poti
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012031046A2
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Lipids suitable for liposomal delivery of protein-coding rna
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
FI4043040T3
(fi)
|
2010-08-31 |
2023-04-04 |
Glaxosmithkline Biologicals Sa |
Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
BR112013008700B8
(pt)
|
2010-10-11 |
2022-10-04 |
Novartis Ag |
Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
|
|
US20120136073A1
(en)
|
2010-11-15 |
2012-05-31 |
Life Technologies Corporation |
Amine-Containing Transfection Reagents and methods for making and using same
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
WO2013006842A2
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
WO2013016058A1
(en)
|
2011-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
|
|
WO2013014073A1
(en)
|
2011-07-22 |
2013-01-31 |
Universite De Strasbourg |
Phospholipid-detergent conjugates and uses thereof
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
LT2750707T
(lt)
|
2011-08-31 |
2019-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
JP6185916B2
(ja)
|
2011-09-21 |
2017-08-23 |
サンガモ セラピューティクス， インコーポレイテッド |
導入遺伝子発現を制御するための方法および組成物
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
ES2745373T3
(es)
|
2011-10-18 |
2020-03-02 |
Dicerna Pharmaceuticals Inc |
Lípidos catiónicos de amina y uso de los mismos
|
|
JP6151707B2
(ja)
|
2011-10-27 |
2017-06-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
薬物内包微小球の形成が可能なｎ−末端で官能基化されたアミノ酸誘導体
|
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
US9463247B2
(en)
|
2011-12-07 |
2016-10-11 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
EP2788006B1
(en)
|
2011-12-07 |
2026-01-07 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
PT2791160T
(pt)
|
2011-12-16 |
2022-07-04 |
Modernatx Inc |
Composições arnm modificado
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
CN102604115B
(zh)
|
2012-02-22 |
2013-07-10 |
天津大学 |
羧甲基壳聚糖季铵盐/pamam核壳纳米粒及制备方法
|
|
AU2013222179B2
(en)
|
2012-02-24 |
2017-08-24 |
Arbutus Biopharma Corporat ion |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US9890391B2
(en)
|
2012-03-27 |
2018-02-13 |
Curevac Ag |
RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
|
|
ES2660129T3
(es)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
|
|
US9446132B2
(en)
|
2012-03-27 |
2016-09-20 |
Sima Therapeutics, Inc. |
Diether based biodegradable cationic lipids for siRNA delivery
|
|
CA2859452C
(en)
|
2012-03-27 |
2021-12-21 |
Curevac Gmbh |
Artificial nucleic acid molecules for improved protein or peptide expression
|
|
US20150306249A1
(en)
|
2012-05-25 |
2015-10-29 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
CA2897752A1
(en)
|
2013-01-10 |
2014-07-17 |
Novartis Ag |
Influenza virus immunogenic compositions and uses thereof
|
|
SG10201710473VA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US20160030527A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods for Treatment of Stroke
|
|
AU2014236250B2
(en)
|
2013-03-14 |
2019-01-03 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
AU2014310933B2
(en)
|
2013-08-21 |
2020-05-14 |
CureVac SE |
Method for increasing expression of RNA-encoded proteins
|
|
SG10201801433XA
(en)
|
2013-08-21 |
2018-04-27 |
Curevac Ag |
Composition and vaccine for treating prostate cancer
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
ES2986054T3
(es)
|
2013-11-18 |
2024-11-08 |
Arcturus Therapeutics Inc |
Lípido catiónico ionizable para el suministro de ARN
|
|
SG10201903381TA
(en)
|
2013-12-30 |
2019-05-30 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2015123576A2
(en)
|
2014-02-17 |
2015-08-20 |
The Brigham And Women's Hospital, Inc. |
Targeted nanoparticle compositions and methods of their use to treat obesity
|
|
EP3110401A4
(en)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
CA3177878A1
(en)
|
2014-04-23 |
2015-10-29 |
Modernatx, Inc. |
Nucleic acid vaccines
|
|
EP3146221B1
(en)
|
2014-05-22 |
2019-05-08 |
Flowserve S.r.l. |
Guide element for a valve actuator and actuator provided with said guide element
|
|
EP3766916B1
(en)
|
2014-06-25 |
2022-09-28 |
Acuitas Therapeutics Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
ES2949172T3
(es)
|
2014-07-16 |
2023-09-26 |
Novartis Ag |
Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
|
|
JP6339884B2
(ja)
|
2014-07-17 |
2018-06-06 |
富士フイルム株式会社 |
イミダゾール化合物およびそれを含有するリポソーム
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
ES2946969T3
(es)
|
2014-12-12 |
2023-07-28 |
CureVac SE |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
|
US20170326225A1
(en)
|
2014-12-16 |
2017-11-16 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
SG11201704681QA
(en)
|
2014-12-30 |
2017-07-28 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
CN104876831B
(zh)
|
2015-04-03 |
2017-05-17 |
苏州圣诺生物医药技术有限公司 |
脂质修饰精胺衍生物及利用该衍生物制备的脂质体
|
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CA2984125A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
WO2016184822A1
(en)
|
2015-05-15 |
2016-11-24 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mrna construct
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
HRP20240865T1
(hr)
|
2015-06-29 |
2024-10-11 |
Acuitas Therapeutics Inc. |
Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
EP3331555A1
(en)
|
2015-08-05 |
2018-06-13 |
CureVac AG |
Epidermal mrna vaccine
|
|
US20190024096A1
(en)
|
2015-08-07 |
2019-01-24 |
Curevac Ag |
Process for the in vivo production of rna in a host cell
|
|
US12258567B2
(en)
|
2015-08-28 |
2025-03-25 |
CureVac SE |
Artificial nucleic acid molecules
|
|
WO2017048770A1
(en)
|
2015-09-15 |
2017-03-23 |
Regulus Therapeutics, Inc. |
Systems, compositions, and methods for formulating nucleic acid compositions
|
|
AU2016324310B2
(en)
|
2015-09-17 |
2021-04-08 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
PT3718565T
(pt)
|
2015-10-22 |
2022-07-20 |
Modernatx Inc |
Vacinas contra vírus respiratórios
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CN113636947A
(zh)
|
2015-10-28 |
2021-11-12 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
US20180312545A1
(en)
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
|
EP4036079B1
(en)
|
2015-12-22 |
2025-11-19 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3397613A1
(en)
|
2015-12-30 |
2018-11-07 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
BR112018016755A2
(en)
|
2016-02-17 |
2018-12-26 |
Curevac Ag |
Zica virus vaccine
|
|
US20170266292A1
(en)
|
2016-03-21 |
2017-09-21 |
The Research Foundation For The State University Of New York |
Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof
|
|
AU2017244143B2
(en)
|
2016-03-30 |
2024-06-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle formulations for CRISPR/Cas components
|
|
EP3445392A1
(en)
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
JP7066632B2
(ja)
|
2016-05-09 |
2022-05-13 |
アストラゼネカ・アクチエボラーグ |
親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
JP7289265B2
(ja)
|
2016-10-26 |
2023-06-09 |
キュアバック エスイー |
脂質ナノ粒子ｍＲＮＡワクチン
|
|
US20190274968A1
(en)
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
JP2020500539A
(ja)
*
|
2016-12-09 |
2020-01-16 |
サンガモ セラピューティクス， インコーポレイテッド |
標的特異的ヌクレアーゼの送達
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
IL301115A
(en)
|
2017-04-28 |
2023-05-01 |
Acuitas Therapeutics Inc |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3661563A4
(en)
|
2017-07-31 |
2021-11-10 |
The Ohio State Innovation Foundation |
BIOMIMETIC NANOMATERIALS AND THEIR USES
|
|
CA3073020A1
(en)
*
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
CA3073018A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
AU2019361129A1
(en)
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN113474328B
(zh)
|
2019-01-11 |
2025-07-11 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
|
KR20220053599A
(ko)
|
2019-08-14 |
2022-04-29 |
아퀴타스 테라퓨틱스 인크. |
핵산을 전달하기 위한 개선된 지질 나노입자
|
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|